Skip to main content

Cenix, Bayer Ink Deal to Screen Druggable Genes Using RNAi

NEW YORK, Dec. 15 (GenomeWeb News) - Cenix BioScience said today that it has signed a deal to use its genome-wide siRNA library to help Bayer screen all known human druggable genes in an effort to identify and validate new drug targets.

 

Cenix said that, using cell-based assays developed in partnership with Bayer researchers, it expects to screen more than 6,000 genes in less than nine months.

 

Under the terms of the deal, Cenix will receive upfront fees and research funding, and is eligible for milestone payments. Bayer will have an option to obtain all rights to new intellectual property generated by the effort.

 

Additional terms were not disclosed.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.